Purpose. There is a lack of consensus about which non-human immunodeficiency virus (HIV) patient groups would benefit from prophylaxis. Here, we analysed an enhanced Pneumocystis jirovecii database to describe the epidemiology of Pneumocystis pneumonia (PCP) and P. jirovecii colonizations in Northern Ireland (NI) with a view to identifying risk groups who may benefit from prophylaxis.
INTRODUCTION
Pneumocystis jirovecii (formerly known as Pneumocystis carinii species) is an atypical fungus that is the causative agent of Pneumocystis pneumonia (PCP), an opportunistic infection seen in immunocompromised individuals. Much of the natural history and epidemiology of P. jirovecii infection is unclear. However, a spectrum of disease appears to exist, ranging from PCP in immunocompromised individuals to mild respiratory illness in children and asymptomatic detections in both immunocompromised and healthy individuals [1, 2] .
In recent years, there has been a reported increase in PCP disease in the non-human immunodeficiency virus (HIV) patient group in developed countries [2, 3] , specifically among individuals with underlying immunodeficiency, cancer patients receiving chemotherapy, bone marrow and solid organ transplant recipients, and patients treated with steroids or other immune suppressive medications [2] . In Northern Ireland (NI), there has been a year-on-year increase in P. jirovecii detections from laboratory data; from 20 episodes in 2010 to 244 episodes in 2014. But whether this reflects non-HIV patients is not known. Additionally, there have been anecdotal reports from clinicians of an increase in PCP. An increase of PCP in non-HIV patient groups is concerning as it is known that mortality varies across patient groups and is higher in non-HIV patients, compared to HIV patients, in part due to delays in diagnosis [2] .
Lower mortality in HIV patients has also been promoted through the existence and acceptance of effective guidelines for PCP prophylaxis in these patients [4] . More recently, in recognition of the fact that prevention and early recognition are optimal management strategies for PCP, guidelines have emerged for non-HIV patient groups including renal transplant patients [2] and haematology patients [5] . The aim of this study was to analyse an enhanced P. jirovecii database to describe the epidemiology of PCP and P. jirovecii colonizations in NI with a view to identifying new risk groups who may benefit from prophylaxis.
METHODS
In July 2011, in response to a cluster of PCP in renal patients at one unit in NI, prospective enhanced surveillance of P. jirovecii positive cases was introduced by the Public Health Agency and the Regional Virus Laboratory (RVL). The RVL is the only provider for P. jirovecii organism detection in NI and during the enhanced surveillance period P. jirovecii was added to the RVL respiratory PCR testing panel. All individuals aged 18 years and over who were inpatients in an acute hospital in NI and had a respiratory sample sent to the RVL were tested for P. jirovecii which included: (1) those with respiratory symptoms or radiological (chest x-ray or computed typography scan)/bronchoscopy investigations where the clinician suspected PCP and requested the test (as was standard practice before the enhanced surveillance period) and (2) those where an individual had a specimen sent to RVL for testing against the respiratory PCR testing panel but where the clinician did not specifically request a test for the P. jirovecii organism (new for the enhanced period). Both upper (throat and nasal) and lower (sputum and broncho-alveolar lavage) respiratory tract samples were included. The enhanced surveillance ran until 31 July 2012.
A case included laboratory-confirmed P. jirovecii detection in an individual with one or more clinical manifestations, sub-categorized as: (1) colonized: clinician's judgement that the illness was not due to PCP and not treated with cotrimoxazole because of the combination of clinical manifestations and lack of typical radiological signs to suggest PCP or (2) PCP: clinician's judgement that the illness was due to PCP and treated with co-trimoxazole because of a clinical presentation compatible with PCP and radiological signs to suggest PCP.
Information collected during the enhanced surveillance period for patients who had the P. jirovecii organism identified included: patient demographics (age, sex), binary variables, including clinical risk groups [haematological malignancy, non-haematological malignancy, chemotherapy (current exposure, excludes steroids)], autoimmune condition, transplant, HIV -any diagnosis (either new during acute PCP or old), steroids (oral) (any exposure), other immunosuppressive drugs (any exposure; may include transplant drugs, disease-modifying anti-rheumatic drugs or biologic therapies), other diagnoses (e.g. cardiovascular disease, diabetes, chronic kidney disease) and other respiratory conditions (e.g. asthma, chronic obstructive pulmonary disorder), and severity [30-day all-cause mortality and intensive care unit (ICU) admission]. Information was also recorded on the specimen type.
The overall incidence of PCP in the NI population aged 18 years and over was determined using the number of confirmed PCP over two denominators: (1) 2012 mid-year population estimates expressed per 1000 population and (2) data of the average occupied bed days for acute hospitals in NI for July 2011-June 2012 expressed per 1000 occupied bed days. Denominator data for disease-specific rate calculations included: HIV population data -all individuals aged 18 years and over who were living with HIV in NI during 2011 and 2012 (source: Survey Of Prevalent HIV Infections Diagnosed), cancer population data: 21 year prevalence for the period 1 July 2011-31 July 2012, which included people who were diagnosed up to 21 years before the study period and who were still alive at 31 July 2012 (source: NI Cancer registry). The denominator for the rate of PCP in non-HIV patient groups was determined as the 2012 mid-year population estimate for individuals 18 years and over minus the number of individuals aged 18 years and over living with HIV in NI during 2012.
Pneumocystis testing
The presence and quantification of P. jirovecii DNA was detected using a duplex quantitative real-time PCR assay targeting both the dihydrofolate reductase and b-tubulin genes [6] . Specimens with a Ct, 'threshold cycle', value of 40 were regarded as positive for P. jirovecii and classified as a laboratory-confirmed P. jirovecii organism for the purposes of case definition. All specimens were quantified using a standard curve constructed from serial log dilutions of a NanoDrop-quantified P. jirovecii positive control.
Analysis strategy
A descriptive summary, expressed as number and proportion, was stratified by case status; individuals with PCP compared to P. jirovecii colonization. The overall incidence of PCP was calculated followed by risk group-specific incidence rates for HIV, cancer and non-HIV patient groups. Demographic, severity (ICU admission, length of stay and 30-day all-cause mortality), specimen type (upper versus lower respiratory sample) and clinical risk group in patients with PCP disease were compared to those without (P. jirovecii colonization only) using logistic regression (univariable analysis). Measures of effect were presented as odds ratios (OR), with 95 % confidence intervals (CI) and likelihood ratio test P-values. The assumption of linearity of the association between age and illness, on the logit scale, was assessed by fitting more complex polynomial functions and simplifying if these functions did not significantly improve the fit of the model. For those exposures where a sampling zero would result in an OR being inestimable, an exact logistic regression was used to calculate the medianunbiased estimate (MUE) of the OR and 95 % CI and Fisher's exact P-values were calculated.
All exposures with OR>1 and a P-value <0.2 were considered for inclusion in the multivariable analysis. Variables which showed a protective effect in the univariate analysis (OR<1) were not considered further as the aim was to identify factors that increased the risk of PCP. Age and sex were included a priori. ORs were presented using multivariable logistic regression and for those exposures for which an OR could not be estimated by this approach, MUEs were obtained using exact logistic regression. In these cases exact score P mid-values were determined.
All analyses were performed using STATA version 13.1.
RESULTS
During the study period, 961 individuals were tested against the RVL respiratory PCR testing panel of which 49 people (5.1 %) identified with the P. jirovecii organism; 36 (73 %) had PCP and 13 (27 %) were colonized. Of the 36 PCP cases, 28 (78 %) were in non-HIV patients of which 18 (18/ 28=64 %) had cancer.
Overall and risk group-specific incidence of PCP The incidence of PCP in individuals aged 18 years and over was 0.03/1000 population (36/1 392 060 persons) and 0.02/ 1000 bed days (36/1 553 699 bed days). The incidence was 9.6/1000 population (5/520) in 2011 and 4.7/1000 population (3/637) in 2012 for people living with HIV. For individuals living with cancer, the incidence of PCP was 0.29/1000 population (18/61 404 persons). Using these estimates, the incidence of PCP in the non-HIV population was 0.02/1000 population (28/1 391 423 persons).
Univariable analysis
There was no difference in the age or sex of individuals with PCP compared to those with colonizations ( Table 1 ).
The odds of PCP compared to P. jirovecii colonization was almost four times higher in those with current exposure to chemotherapy (OR 3.5; 95 % CI 0.67, 18.2; Table 2), five times higher for those diagnosed with HIV (OR 4.8; 95 % CI 0.66, ¥; Table 2 ) and almost six times higher for those ever exposed to another immunosuppressive drug (OR 5.62; 95 % CI 0.79, ¥; Table 2 ).
There was no statistically significant difference in the odds of PCP, compared to P. jirovecii colonization, for individuals with a haematological malignancy (P=0.9), a non-haematological malignancy (P=0.6), an autoimmune condition (P=0.4), a transplant (P=0.6), exposure to steroids (P=0.5), other diagnoses (P=0.7), or those with another respiratory disease (P=0.4; Table 2 ).
There was no difference between the proportion of individuals admitted to ICU with PCP disease (13/36; 36 %) or P. jirovecii colonization (5/13; 39 %; P=0.9, Table 3 ). There was no difference in the length of stay for individuals with PCP disease (median 19.5 days) compared to those that were colonized (19 days), excluding individuals whose reason for discharge was death within 30 days of their positive specimen (Table 3 ; P=0.9).
The 30-day all-cause mortality was 27.8 % (10 cases) in those with PCP disease compared to 30.8 % in those with P. jirovecii colonization (four cases) which was not statistically different (Table 3 ; P=0.8). In those with PCP disease, the highest mortality was observed in individuals who had been exposed to chemotherapy (6/14=42.9 %), followed by those with a haematological malignancy (5/12=41.7 %), another respiratory diagnosis (5/13=38.5 %) and a non-haematological malignancy (3/8=37.5 %).
The majority of both PCP disease and P. jirovecii colonizations were reported from lower respiratory tract specimens 26/36 (72 %) and 9/13 (69 %) for disease and colonizations respectively. There was no statistically significant difference in the odds of PCP disease in those with an upper compared to those with a lower respiratory tract specimen [OR 1.16 (95 % CI 29, 4.62), P=0.8].
Multivariable analysis
The final model consisted of a non-linear function of age, sex, exposure to chemotherapy, HIV diagnosis and exposure to other immunosuppressive drugs. Adjusting for all other factors, the odds of PCP was not significantly associated with sex, but there was some evidence of a quadratic association between age and disease (P=0.15). It was found to be Ushaped with the odds of PCP increasing with age from 24 to 40 years, with a decline afterwards (but with only 10 % of the sample aged under 42 years). The odds of PCP were over eight times higher in those exposed to chemotherapy [adjusted MUE of the OR (AMUE OR) 8.73; 95 % CI 0.84, ¥; Table 4 ]. The odds of PCP were more than 16 times higher in those Table 4 ). Finally, the odds of PCP were 12 times higher in those who had been exposed to other immunosuppressive drugs (AMUE OR 12.1; 95 % CI 1.94, ¥; Table 4 ).
DISCUSSION
Following a report of an increase in PCP in non-HIV patient groups in NI this study aimed to describe the epidemiology of P. jirovecii colonizations and PCP to identify patient risk groups who may benefit from targeted preventive measures. The analysis showed that the burden of PCP now occurs in non-HIV patients. Further, within this group almost half of PCP is observed in cancer patients who have a higher 30-day all-cause mortality compared to other risk groups.
PCP risk groups
An HIV diagnosis, exposure to chemotherapy and exposure to other immunosuppressive drugs were all independent risk factors for PCP disease. The association between HIV status and PCP diagnosis is long established [2, 4] . Indeed, prior to the introduction of preventive measures, as well as treatment advances for HIV, up to 80 % of disease was in this group [4] . This profile has now reversed, with 78 % of cases now belonging to the non-HIV group.
Despite this change, specific details about the risk profile for those exposed to chemotherapy and other immunosuppressive drugs is still lacking. In comparison, objective measures for HIV patients are documented and universally accepted [4] . Indeed, while chemotherapy has been reported as a risk factor for PCP in other studies it is not clear if it is chemotherapy or the malignancy per se that increases the risk of PCP [2, 3] . There is also a lack of data about how the timing of chemotherapy, relative to the PCP diagnosis, or the dose or duration affects the risk of PCP. In this study, risk group sub-analysis for PCP disease was conducted by examining those exposed to immunosuppressive drugs, including renal transplant, rheumatoid arthritis and inflammatory bowel disease. While there have been published studies suggesting an increased risk of PCP among similar groups [7, 8] this could not be investigated further in this study because of the small numbers.
Severity indicators
While there were differences in the risk of PCP within the clinical risk group, when compared to P. jirovecii colonization, there was an observed lack of difference for the chosen indicators of severity. For example, just over one-third of patients with P. jirovecii colonization and PCP were admitted to ICU. While an ICU admission has a significant impact on the patient, it also places a substantial burden on the healthcare system, which can be exacerbated by increased lengths of stay. Both groups experienced a length of stay of almost 3 weeks. There was no statistically significant difference detected in 30-day all-cause mortality between individuals with PCP compared to those with P. jirovecii colonization (28 and 31 %, respectively). The observed mortality in those with PCP supports the case for testing all individuals from certain risk groups with clinical manifestations early in the course of their illness, with treatment initiated as early as possible. The significance of similar allcause mortality in those with P. jirovecii colonization is less clear. It is possible that because the colonized individuals present with multiple co-morbidities they already have an increased likelihood of mortality. It may also be due to misclassification of colonization status but the triangulation of different sources of information should minimize this risk.
Given that the evidence suggests that colonization is a potential risk factor for developing PCP, in the case of decreased immunity, it does support the need for better diagnostics and on-going monitoring of such patients to identify any change of diagnosis [9, 10] .
Strengths and limitations
One of the big strengths of this study was that it was a prospective design which attempted to capture all patients with P. jirovecii, regardless of whether the clinician requested a test for PCP. However, there are a number of limitations. While the sampling strategy was unlikely to miss the classical presentation of PCP the estimate of P. jirovecii colonization may be underestimated because it only reflects hospitalized patients with respiratory symptoms who have a sample sent to RVL. While real-time PCR methods were used for the detection of the P. jirovecii organism during this study, the interpretation of the results is still challenging as standard quantities to diagnose PCP disease from colonization have not been established [10] . Indeed, given that PCP is an immune pathology low fungal load is not necessarily representative of colonization only. In our study, laboratory data was combined with clinical presentation and the clinician's decision to treat the patient for infection. This multimodal approach increases the likelihood that cases of colonization were correctly identified but does not completely rule out that some cases of pneumonia with a different aetiology will be interpreted as PCP in the presence of a positive P. jirovecii result and vice versa [11] . While existing guidelines cite the use of lower respiratory tract specimens for the diagnosis of PCP, [2, 4] we also included specimens from the upper respiratory tract in our analysis to reflect the enhanced surveillance programme. It is conceivable that this may affect the odds of PCP for different patient risk groups (specimen type may be an effect modifier). We found using multiple tests for interaction between risk group and specimen type that this was not the case. For this reason, pooled data (upper and lower respiratory tract specimens) were presented. One final limitation is that this study relied on data that were collected as part of a surveillance programme which was implemented for public health purposes. Because of this we had no control over the sample size and it is possible that because of small numbers the study could be underpowered. However, we were still able to detect known risk factors, for example, the association with HIV status, and therefore we feel that we can be confident in the results.
In order to address some of the limitations highlighted in this paper, and the challenges surrounding an international definition for P. jirovecii colonization and PCP we recommend further consideration be given to introducing an enhanced surveillance system for P. jirovecii. The aim would be to collect more detailed clinical information, including oxygen levels, to support more robust case definitions as well as to examine the feasibility of including upper and lower respiratory tract specimens for diagnosis. Finally, it would also be useful to consider genotyping of the isolates to gather further knowledge about transmission which was not addressed in this study.
Conclusion
The data reported here support a shift in burden to the HIV-negative patient risk groups and adds knowledge to the increased risk of PCP in those exposed to chemotherapy or immunosuppressive drugs. In the absence of objective criteria for prophylaxis in non-HIV patients, there is a significant challenge around risk assessment in these groups. We recommend that individuals from risk groups that present with clinical manifestations should be tested for P. jirovecii early in the course of their illness. To facilitate this, awareness of PCP guidelines for prevention in non-HIV patients should be promoted across different specialities. We also recommend research to address specific risk assessments in the non-HIV population. Until this evidence is available clinicians should continue to assess the need for prophylaxis on a case-by-case basis.
Funding information
The authors received no specific grant from any funding agency.
